Navigation Links
NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
Date:8/14/2014

any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ability to comply with the closing conditions or other conditions that might prevent the closing of the offering, the use of proceeds from the offering of the Notes, the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions, risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Logo - http://photos.prnewswire.com/prnh/20110329/SF73084LOGO


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vermillion Announces Additions to Commercial Management Team
2. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
3. Veracyte, Inc. Announces Second Quarter 2014 Financial Results
4. Hanger Announces Appointment of Asif Ahmad to Board of Directors
5. BiOptix Announces Additional $1.4M in Funding to Aid in Commercialization and Working Capital Needs
6. Perrigo Company plc Announces Quarterly Dividend
7. Kindred Biosciences Announces Second Quarter 2014 Financial Results
8. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
9. WuXi PharmaTech Announces Second-Quarter 2014 Results
10. Nutrastar International Inc. Announces Second Quarter 2014 Results
11. Novogen Announces Results of General Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... BETHESDA, Md. , May 28, 2015 /PRNewswire-USNewswire/ ... that it will be a supporting organization of ... assurance and sterilization in 2016. Johnson ... a series of high-profile superbug infections in endoscopes. ... world health issues between 1976 and 2003 on ...
(Date:5/28/2015)... SAN DIEGO , May 28, 2015 /PRNewswire/ ... a clinical-stage biopharmaceutical company leveraging its molecular adhesion ... therapies for sickle cell disease, heart failure, and ... be resigning from the Company,s Board of Directors. ... potential conflict of interest given his role as ...
(Date:5/28/2015)... 2015 Compassion & Choices today is pleased to ... that would authorize the option of medical aid in dying ... The legislation, the ... mentally competent adults with six months or less to live ... painlessly and peacefully end an unbearable dying process. A vote ...
Breaking Medicine Technology:PDA Announces Support for the Johnson & Johnson Kilmer Conference 2Mast Therapeutics Announces Change In Board Of Directors 2Mast Therapeutics Announces Change In Board Of Directors 3Mast Therapeutics Announces Change In Board Of Directors 4California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 3
... http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, OTC: DMYDY), STOCKHOLM, ... that the Swedish Medical Products,Agency (MPA) has approved the Company,s ... Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), "I am ...
... Asthma and Exercise-Induced ... Bronchoconstriction -, PLYMOUTH MEETING, Pa., ... development partner,MedImmune, has initiated its fourth phase 2a clinical trial of ... This clinical trial is designed to assess the,potential of MEDI-528 in ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma 2Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma 3Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma 4
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... Dr. Farhad Rafizadeh, specializes in delivering world-class results. ... of Plastic Surgery and a background in art, Dr. ... look. His unique approach to Plastic Surgery involves ... addition, his practice delivers a superior level of comfort ...
(Date:5/28/2015)... As the summer approaches, many people will head ... to make safety a top priority, however, and that’s why ... According to the Centers for Disease Control, 10 people die ... boating incidents. Additionally, the National Safety Council says drowning is ... 4. , Amica is sharing the following tips from ...
(Date:5/28/2015)... Trends Investing ” was featured on NewsWatch as part of ... medium, and large businesses making an impact in their industry. ... the business review and shared with viewers how this website ... money. , The idea, “let your money work for you” ... how to succeed are two different things. So if ...
(Date:5/28/2015)... More than 300 locations of the ... to help the Muscular Dystrophy Association save and improve ... life-threatening diseases that limit muscle strength and mobility by ... From June 1 to June 30, sweetFrog associates will ... to help send local children affected by neuromuscular diseases ...
(Date:5/28/2015)... BC (PRWEB) May 28, 2015 ... Research ( http://www.idataresearch.com ), the shoulder reconstruction device ... orthopedic small bone & joint market in 2014. ... shoulder arthroplasty procedures in the U.S. due to ... improved device technology resulting in greater patient outcomes. ...
Breaking Medicine News(10 mins):Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Splash! Amica Shares 6 Swimming Safety Tips 2Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3
... 21 (HealthDay News) -- No new patients will be ... controversial diabetes drug Avandia until further notice, the U.S. ... the partial clinical trial hold, those patients already enrolled ... trial will be allowed to continue to participate, the ...
... Hospitals Case Medical Center Center for AIDS Research ... renewal grant from the National Institutes of Health ... and technological support to researchers working on HIV-related ... Medical Center, MetroHealth Medical Center, Cleveland Clinic, and ...
... (HealthDay News) -- The cancer drug Avastin should no longer ... Food and Drug Administration advisory panel voted Tuesday, saying the ... represented a setback for Avastin, which is the world,s best-selling ... Avastin is sold by drug maker Roche,s Genentech unit, ...
... ,The Lancet Series on HIV in people ... at the International AIDS conference in Vienna, reports that ... injecting drug users (IDUs), health providers must focus less ... and more on conditions of health delivery that create ...
... Gay and bisexual men enrolled in a long-term study of ... experience psychosocial health problems later in life that could put ... Pittsburgh Graduate School of Public Health researchers at the ... more than 1,000 HIV-positive and negative gay and bisexual men ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, July ... older adults, meant to be humorous, shows a vulture on a ... might find the humor unsettling, the blunt message is right on ... is better than none, exercise experts say. Yet they also ...
Cached Medicine News:Health News:FDA Puts Partial Hold on Avandia Safety Study 2Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 2Health News:$9M NIH grant renewal awarded to Case Western Reserve/UHCMC Center for AIDS Research 3Health News:FDA Advisers Say Avastin Shouldn't Be Used for Breast Cancer 2Health News:Improved treatment access requires end to portrayal of drug abusers as already dead 2Health News:Improved treatment access requires end to portrayal of drug abusers as already dead 3Health News:'Get Moving' Can Be Vital Advice for Seniors 2Health News:'Get Moving' Can Be Vital Advice for Seniors 3
Instrument for transphenoidal hypophysectomy, bayonet-shaped, dissector, sharp inner edge, left....
Papavero-caspar specula for trans-sphenoidal hypophysectomy....
... Triad Facet Screws ... a posterior tension band ... construct. Through utility of ... percutaneous placement of Triad ...
Cushing pituitary scoop, malleable, silver-plated....
Medicine Products: